The global meningococcal vaccines market size reached US$ 3.6 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 8.01% during 2023-2032.
Meningococcal vaccine refers to a biological substance administered for the prevention of meningitis, which is a contagious infection of the membranes surrounding the spinal cord and the brain. The three main kinds of meningococcal vaccines include conjugate, polysaccharide and subcapsular meningococcal vaccines. They are administered to infants, children and adults to immunize them against the invasive disease and target meningococcal bacteria A, B, C, W-135 and Y. Once the vaccine is administered, antibodies are formed to fight the bacteria and create an immune response to prevent the infection in the future.
The increasing prevalence of the meningococcal disease among young children and adolescents across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising health consciousness among the masses and the adoption of routine immunization are providing a thrust to the market growth. Meningococcal vaccine aids in preventing the disease and minimizing the long-term effects, such as temporary or permanent deafness, loss of vision and motor skills, seizure and neurological damage.
In line with this, governments of both developed and emerging economies are launching extensive public health programs while emphasizing on the immunization of special risk groups, such as tourists and military personnel, to contain the risks of infections. Additionally, various product innovations, such as the development of ready-to-use liquid formulations that do not require reconstitution, are also contributing to the market growth. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
Meningococcal vaccine refers to a biological substance administered for the prevention of meningitis, which is a contagious infection of the membranes surrounding the spinal cord and the brain. The three main kinds of meningococcal vaccines include conjugate, polysaccharide and subcapsular meningococcal vaccines. They are administered to infants, children and adults to immunize them against the invasive disease and target meningococcal bacteria A, B, C, W-135 and Y. Once the vaccine is administered, antibodies are formed to fight the bacteria and create an immune response to prevent the infection in the future.
The increasing prevalence of the meningococcal disease among young children and adolescents across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising health consciousness among the masses and the adoption of routine immunization are providing a thrust to the market growth. Meningococcal vaccine aids in preventing the disease and minimizing the long-term effects, such as temporary or permanent deafness, loss of vision and motor skills, seizure and neurological damage.
In line with this, governments of both developed and emerging economies are launching extensive public health programs while emphasizing on the immunization of special risk groups, such as tourists and military personnel, to contain the risks of infections. Additionally, various product innovations, such as the development of ready-to-use liquid formulations that do not require reconstitution, are also contributing to the market growth. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global meningococcal vaccines market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on vaccine type, composition, vaccine serotype, distribution channel and end user.Breakup by Vaccine Type:
- Conjugate
- Polysaccharide
- Subcapsular
Breakup by Composition:
- Mono Vaccines
- Combination Vaccines
Breakup by Vaccine Serotype:
- MenACWY
- MenB & Manic
- MenC
- MenA
- MenAC
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
- Others
Breakup by End User:
- Pediatric
- Adult
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being GlaxoSmithKline Plc, Hualan Biological Engineering Inc., Incepta Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Sanofi S.A., Serum Institute of India Ltd. and Walvax Biotechnology Co. Ltd.Key Questions Answered in This Report:
- How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global meningococcal vaccines market?
- What are the key regional markets?
- What is the breakup of the market based on the vaccine type?
- What is the breakup of the market based on the composition?
- What is the breakup of the market based on the vaccine serotype?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global meningococcal vaccines market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary13 Value Chain Analysis15 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Meningococcal Vaccines Market
6 Market Breakup by Vaccine Type
7 Market Breakup by Composition
8 Market Breakup by Vaccine Serotype
9 Market Breakup by Distribution Channel
10 Market Breakup by End User
11 Market Breakup by Region
12 SWOT Analysis
14 Porters Five Forces Analysis
16 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- GlaxoSmithKline Plc
- Hualan Biological Engineering Inc.
- Incepta Pharmaceuticals Limited
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Serum Institute of India Ltd.
- Walvax Biotechnology Co. Ltd.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 137 |
Published | August 2024 |
Forecast Period | 2023 - 2032 |
Estimated Market Value ( USD | $ 3.6 Billion |
Forecasted Market Value ( USD | $ 7.2 Billion |
Compound Annual Growth Rate | 8.0% |
Regions Covered | Global |
No. of Companies Mentioned | 8 |